A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple Negative Breast Cancer

CONCLUSIONS: The median OS increased by more than 2-fold in patients with clinical benefit. The therapy is a well-tolerated treatment in heavily pretreated mTNBC patients. Early detection of increased effector and effector memory CD8 T cells and myeloids correlate with response and non-response, respectively.PMID:35877117 | DOI:10.1158/1078-0432.CCR-22-0622

Source: Clinical Genitourinary Cancer - July 25, 2022 Category: Cancer & Oncology Authors: Kai Sun Yitian Xu Licheng Zhang Polly Niravath Jorge Darcourt Tejal Patel Bin S Teh Andrew M Farach Carlo Guerrero Sunil Mathur Mark A Sultenfuss Nakul Gupta Mary R Schwartz Susan L Haley Sindhu Nair Xiaoxian Li Thi Truc Anh Nguyen Joseph D Butner Joe Ens Source Type: research